• ARYx Therapeutics Inc., of Fremont, Calif., said it has completed its initial public offering, which included 5 million shares of its common stock at $10 per share. (See BioWorld Today, Nov. 8, 2007.) ATEL Ventures Inc., of San Francisco, provided debt and equity financing.

• TapImmune Inc., of Vancouver, British Columbia, said the U.S. Patent and Trademark Office has granted the company's petition to revive U.S. Patent Application 10/046,542. The firm said the patent application is key for the company because it describes a preferable delivery method for the TAP gene sequences and serves as the basis for further expansion of the firm's technology. TapImmune said it submitted additional claims with respect to the subject matter disclosed in the patent, including filing further continuations. In addition, TapImmune, which specializes in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announced the closing of a bridge financing of $445,000. The company said that the cash infusion will see it through the first half of next year and allow for continued development and manufacturing contracts to be pursued.

No Comments